Insight Molecular Diagnostics Inc.
NASDAQ:IMDXMedical - Diagnostics & Research
+$0.13 today
- Market cap
- $52.08M
- Beta
- 1.79
- P/E (TTM)
- -3.9
- EPS (TTM)
- -$1.39
Volume 0.64M
Average 0.38M
IMDX Accumulated OCI
Accumulated other comprehensive income: unrealized gains and losses, such as currency translation, recorded outside net income.
Insight Molecular Diagnostics Inc.NASDAQ: IMDX
Accumulated OCI · Q1 FY2026 · quarter ended Mar 2026
Accumulated OCI rises 73.2% from a year ago
Accumulated OCI stood at $71K at the end of Q1 FY2026, up 73.2% from a year earlier and down 17.4% from the prior quarter. Over 3 fiscal years it compounded at +30.2% a year.
Context
- Accumulated OCI amounted to 0.2% of total assets at the end of Q1 FY2026, up 0.1 pp from a year earlier.
- Accumulated OCI increased in 2 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether Accumulated OCI keeps rising in the next quarterly balance sheet after a +73.2% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Accumulated OCI history
USD · from the balance sheet
- Latest · FY2025
- 86K USD
- Year-over-year change
- +309.5%
- 4-year CAGR
- +23.5%
| Period | Period end | Accumulated OCI | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 86K | +309.5% |
| FY2024 | 2024-12-31 | 21K | -57.1% |
| FY2023 | 2023-12-31 | 49K | +25.6% |
| FY2022 | 2022-12-31 | 39K | +5.4% |
| FY2021 | 2021-12-31 | 37K | — |
Accumulated OCI vs competitors
How IMDX compares with its peers on the latest reported figures
- IMDX's Mar 2026 Accumulated OCI of $71K is the 2nd highest of the 10 companies compared; the peer median is -$37K.
- Its year-over-year change of +73.2% is the highest of 9, against a peer median of -173.4%.
- Accumulated OCI amounts to 0.2% of total assets for IMDX, versus a peer median of 0.0%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $55.65M | +4.8% | +17.4% | 28.7% | |
IMDXInsight Molecular Diagnostics Inc. | Mar 2026 | $71K | +73.2% | +30.2% | 0.2% |
| Mar 2026 | $0 | — | — | 0.0% | |
| Mar 2026 | -$2K | -125.0% | +10.1% | 0.0% | |
| Mar 2026 | -$11K | -178.6% | — | 0.0% | |
| Mar 2026 | -$37K | -184.6% | — | 0.0% | |
| Mar 2026 | -$41K | -441.7% | — | 0.0% | |
| Mar 2026 | -$59K | -168.2% | — | 0.0% | |
| Mar 2026 | -$322K | -848.8% | — | 0.1% | |
| Mar 2026 | -$2.51M | +54.5% | — | 4.2% | |
| Peer median (excluding IMDX) | -$37K | -173.4% | +13.8% | 0.0% | |
Competitors are the stored peer set for IMDX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 32.95M | 19.99M | 9.43M | 8.64M | 11.58M |
| Short-term Investments | 904K | 433K | 0 | 0 | 0 |
| Net Receivables | 1.44M | 2.01M | 484K | 1.61M | 1.13M |
| Inventory | 304K | 0 | 0 | 410K | 446K |
| Other Current Assets | 2.94M | 2.12M | 782K | 1.1M | 2.15M |
| Total Current Assets | 39.14M | 25.54M | 10.7M | 11.76M | 15.31M |
| Property, Plant & Equipment (Net) | 8.37M | 10.85M | 5.44M | 2.76M | 2.82M |
| Goodwill | 18.68M | 0 | 0 | 0 | 0 |
| Intangible Assets | 61.72M | 61.63M | 56.6M | 14.61M | 0 |
| Long-term Investments | 0 | 0 | 0 | 1.7M | 607K |
| Tax Assets | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Assets | 31.65M | 2.07M | 2.16M | 4.26M | 7.03M |
| Total Non-current Assets | 120.42M | 74.56M | 64.19M | 23.32M | 10.45M |
| Total Assets | 159.56M | 100.09M | 74.89M | 35.08M | 25.76M |
| Account Payables | 1.81M | 1.25M | 953K | 2.28M | 2.54M |
| Short-term Debt | 1.31M | 0 | 0 | 0 | 0 |
| Tax Payables | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 6.71M | 4.43M | 4.01M | 2.17M | 2.89M |
| Total Current Liabilities | 14.12M | 12.11M | 7.19M | 7.28M | 12.08M |
| Long-term Debt | 0 | 0 | 0 | 0 | 0 |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Non-current) | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Liabilities | 76.68M | 45.66M | 45.03M | 37.71M | 43.46M |
| Total Non-current Liabilities | 80.23M | 48.39M | 47.23M | 40.08M | 45.15M |
| Total Liabilities | 94.35M | 60.5M | 54.42M | 47.36M | 57.22M |
| Common Stock | 252.95M | 294.93M | 310.3M | 338.24M | 369.21M |
| Retained Earnings | (187.77M) | (260.68M) | (289.88M) | (350.54M) | (400.76M) |
| Accumulated OCI | 37K | 39K | 49K | 21K | 86K |
| Other Stockholders Equity | 0 | (0) | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | 65.22M | 39.59M | 20.47M | (12.27M) | (31.46M) |
| Total Debt | 5.68M | 3.54M | 2.87M | 3.66M | 3.5M |
| Net Debt | (27.27M) | (16.45M) | (6.56M) | (4.97M) | (8.09M) |
Insight Molecular Diagnostics Inc.
NASDAQ:IMDX
Intrinsic Alpha fair value
Locked
Current Price
$1.59
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.